Copyright
©The Author(s) 2021.
World J Clin Oncol. Nov 24, 2021; 12(11): 1037-1046
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1037
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1037
Effectiveness outcome | All patients (n = 48) | Papillary RCC (n = 24) | Chromophobe RCC (n = 9) |
Response rate (RECIST 1.1), n (%) | |||
Partial responses | 13 (27.1) | 6 (25.0) | 2 (22.2) |
Complete responses | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Stable disease | 27 (56.3) | 14 (58.3) | 5 (55.5) |
Progressions of disease | 6 (12.5) | 3 (12.5) | 1 (11.1) |
Not evaluable | 2 (4.2) | 1 (4.2) | 1 (11.1) |
Disease control rate | 40 (83.3) | 20 (83.3) | 7 (77.8) |
PFS | |||
Median (mo) (95%CI) | 12.3 (3.6-20.9) | - | - |
Rate of patients progression free at 6 mo | 67.8% | - | - |
Rate of patients progression free at 12 mo | 49.0% | - | - |
OS | |||
Median (mo) (95%CI) | 27.6 (18.3-37.1) | - | - |
Rate of patients alive at 12 mo | 82.7% | - | - |
Rate of patients alive at 24 mo | 62.0% | - | - |
- Citation: Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World J Clin Oncol 2021; 12(11): 1037-1046
- URL: https://www.wjgnet.com/2218-4333/full/v12/i11/1037.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i11.1037